Imaging cancer using a new PET/CT agent targeting Nectin-4
A Study to Evaluate 68Ga-N188 PET/CT Imaging of Nectin-4 Expression in Malignant Tumors
This study is testing a new imaging agent to see if it can help better detect certain cancers, like bladder cancer, in patients who already have or might have cancer.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 203 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Peking University First Hospital Academic / other |
| Locations | 1 site (Beijing, Beijing Municipality) |
| Trial ID | NCT05593107 on ClinicalTrials.gov |
What this trial studies
This study investigates the use of a novel PET imaging agent, [68Ga]N188, which specifically targets the Nectin-4 protein that is overexpressed in various malignancies, particularly those of epithelial origin like bladder cancer. By utilizing this agent, the study aims to improve the diagnosis and research of cancers with high Nectin-4 expression. Patients with confirmed or suspected cancer will undergo imaging with [68Ga]N188 following a recent 18F-FDG PET/CT scan to assess the effectiveness of this new imaging approach.
Who should consider this trial
Good fit: Ideal candidates for this study are adults with confirmed or suspected malignancies, particularly those expressing high levels of Nectin-4.
Not a fit: Patients who are pregnant or lactating, or those planning to become pregnant within six months, will not benefit from this study.
Why it matters
Potential benefit: If successful, this imaging technique could lead to more accurate diagnoses and better-targeted treatments for patients with specific types of cancer.
How similar studies have performed: While this approach is novel in targeting Nectin-4 for imaging, similar studies using targeted imaging agents have shown promise in other malignancies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * patients with confirmed or suspected cancer; * 18F-FDG PET/CT within 1 week; * Signed written informed consent. Exclusion Criteria: * Pregnant and lactating women; * Female patients plan to become pregnant within 6 months.
Where this trial is running
Beijing, Beijing Municipality
- Peking University First Hospital — Beijing, Beijing Municipality, China (Recruiting)
Study contacts
- Study coordinator: Jianhua Zhang, Dr.
- Email: zjhjn820@163.com
- Phone: +861083572791
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.